Insider Transactions in Q3 2025 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2025
|
Colleen F Reitan Director |
SELL
Open market or private sale
|
Direct |
18,000
-16.14%
|
$8,442,000
$469.51 P/Share
|
|
Sep 09
2025
|
Colleen F Reitan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+48.95%
|
$1,800,000
$100.65 P/Share
|
|
Aug 29
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,474
-2.06%
|
$1,559,826
$449.02 P/Share
|
|
Aug 19
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,455
-1.15%
|
$666,390
$458.88 P/Share
|
|
Aug 18
2025
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
11,250
-40.1%
|
$5,062,500
$450.0 P/Share
|
|
Aug 18
2025
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+28.62%
|
$787,500
$70.2 P/Share
|
|
Aug 18
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,396
-0.74%
|
$630,992
$452.31 P/Share
|
|
Aug 18
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,979
-1.44%
|
$3,154,508
$452.31 P/Share
|
|
Aug 18
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.55%
|
$1,027,848
$452.31 P/Share
|
|
Aug 18
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,396
-0.58%
|
$630,992
$452.31 P/Share
|
|
Aug 18
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
1,396
-0.77%
|
$630,992
$452.31 P/Share
|
|
Aug 15
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+10.57%
|
-
|
|
Aug 15
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,252
+18.4%
|
-
|
|
Aug 15
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,644
+8.14%
|
-
|
|
Aug 15
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+8.46%
|
-
|
|
Aug 15
2025
|
Pushkal Garg EVP Chief R&D |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+11.0%
|
-
|
|
Aug 14
2025
|
Dennis A Ausiello Director |
SELL
Open market or private sale
|
Direct |
31,448
-25.78%
|
$13,742,776
$437.26 P/Share
|
|
Aug 14
2025
|
Dennis A Ausiello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
31,448
+21.87%
|
$4,497,064
$143.69 P/Share
|
|
Jul 01
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
7,763
+26.74%
|
-
|